These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Efficacies and clinical roles of new antifungal agents]. Tokimatsu I, Kadota J. Nihon Ishinkin Gakkai Zasshi; 2006; 47(3):155-9. PubMed ID: 16940948 [Abstract] [Full Text] [Related]
23. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin. Shi JY, Xu YC, Shi Y, Lü HX, Liu Y, Zhao WS, Chen DM, Xi LY, Zhou X, Wang H, Guo LN. Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656 [Abstract] [Full Text] [Related]
24. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Clemons KV, Schwartz JA, Stevens DA. Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507 [Abstract] [Full Text] [Related]
25. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, Alcazar-Fuoli L, Mellado E, Buitrago MJ, Rodriguez-Tudela JL. Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937 [Abstract] [Full Text] [Related]
29. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, Kontoyiannis DP, Hachem RY. Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720 [Abstract] [Full Text] [Related]
30. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. Sivak O, Bartlett K, Risovic V, Choo E, Marra F, Batty DS, Wasan KM. J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198 [Abstract] [Full Text] [Related]
31. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Domínguez-Gil A, Martín I, García Vargas M, Del Castillo A, Díaz S, Sánchez C. Clin Drug Investig; 2007 Jun; 27(3):197-205. PubMed ID: 17305414 [Abstract] [Full Text] [Related]
32. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature. Karthaus M. Eur J Med Res; 2011 Apr 28; 16(4):145-52. PubMed ID: 21486728 [Abstract] [Full Text] [Related]
37. Invasive Aspergillus fumigatus infection after Plasmodium falciparum malaria in an immuno-competent host: case report and review of literature. Eckerle I, Ebinger D, Gotthardt D, Eberhardt R, Schnabel PA, Stremmel W, Junghanss T, Eisenbach C. Malar J; 2009 Jul 20; 8():167. PubMed ID: 19619319 [Abstract] [Full Text] [Related]
38. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation. Wieland T, Liebold A, Jagiello M, Retzl G, Birnbaum DE. J Heart Lung Transplant; 2005 Jan 20; 24(1):102-4. PubMed ID: 15653389 [Abstract] [Full Text] [Related]
40. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker-Woudenberg IA. J Antimicrob Chemother; 2006 Apr 20; 57(4):732-40. PubMed ID: 16464895 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]